Fecha de recepción: 20/09/2017 – Fecha de aceptación: 22/11/2017
Lázaro Cebas A, Cortijo Cascajares S, Goyache Goñi MP, Ferrari Piquero JM
Servicio de Farmacia. Hospital Universitario 12 de Octubre. Madrid (España)
Andrea Lázaro Cebas
Hospital Universitario 12 de Octubre
(Servicio de Farmacia)
Avda. Córdoba, s/n
Correo electrónico: firstname.lastname@example.org
Objectives: To determine the costs derived from the use of the intravenous (iv) and subcutaneous (sc) formulations of trastuzumab and to perform a cost analysis in 3 different scenarios: before the introduction of sc trastuzumab, currently with a 70% use of the sc formulation and finally a scenario in which the use of the sc formulation was increased to 90%.
Materials and methods: A cross-sectional study carried out during 2016. Demographic and therapeutic variables were collected. To perform the cost analysis, direct (pharmacological, consumables and health personnel) and indirect (loss of labour productivity) costs were considered. A vial sharing of 90% was considered to calculate the pharmacological cost of the iv administration.
Results: 153 patients (110 with early breast cancer and 43 with metastatic breast cancer) were treated with trastuzumab during 2016. The mean number of cycles received were 7.37±4.06 in early breast cancer, 8.32±5.44 in first line metastatic breast cancer and 6.21±5.89 in successive lines of metastatic breast cancer. Compared to the initial scenario in which the 100% of the patients were treated with IV trastuzumab, the use of the sc formulation has resulted in a total annual savings of € 128,583.00. The annual savings that could be achieved by increasing the use of the sc formulation to 90% would be € 36,738.00.
Conclusions: The use of sc trastuzumab has resulted in considerable savings considering direct and indirect costs. The savings could be increased by raising the use of the SC formulation with respect to the IV.
Key Words: Subcutaneous, trastuzumab, breast cancer, resource use.
Download PDF: Impacto económico de la utilización de trastuzumab subcutáneo en un hospital de tercer nivel